These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 25311995)

  • 1. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).
    McKone EF; Borowitz D; Drevinek P; Griese M; Konstan MW; Wainwright C; Ratjen F; Sermet-Gaudelus I; Plant B; Munck A; Jiang Y; Gilmartin G; Davies JC;
    Lancet Respir Med; 2014 Nov; 2(11):902-910. PubMed ID: 25311995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
    Rowe SM; Daines C; Ringshausen FC; Kerem E; Wilson J; Tullis E; Nair N; Simard C; Han L; Ingenito EP; McKee C; Lekstrom-Himes J; Davies JC
    N Engl J Med; 2017 Nov; 377(21):2024-2035. PubMed ID: 29099333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
    Uluer AZ; MacGregor G; Azevedo P; Indihar V; Keating C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Rubenstein RC; Taylor-Cousar JL; Tullis E; Yonker LM; Chu C; Lam AP; Nair N; Sosnay PR; Tian S; Van Goor F; Viswanathan L; Waltz D; Wang LT; Xi Y; Billings J; Horsley A; ;
    Lancet Respir Med; 2023 Jun; 11(6):550-562. PubMed ID: 36842446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One
    Wainwright C; McColley SA; McNally P; Powers M; Ratjen F; Rayment JH; Retsch-Bogart G; Roesch E; Ahluwalia N; Chin A; Chu C; Lu M; Menon P; Waltz D; Weinstock T; Zelazoski L; Davies JC
    Am J Respir Crit Care Med; 2023 Jul; 208(1):68-78. PubMed ID: 37154609
    [No Abstract]   [Full Text] [Related]  

  • 6. Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR.
    Milla CE; Ratjen F; Marigowda G; Liu F; Waltz D; Rosenfeld M;
    Am J Respir Crit Care Med; 2017 Apr; 195(7):912-920. PubMed ID: 27805836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world impact of ivacaftor in people with cystic fibrosis and select ivacaftor-responsive mutations.
    McKinnon C; Thorat T; Craft A; Higgins M
    BMJ Open Respir Res; 2024 Jul; 11(1):. PubMed ID: 39074961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis.
    Gramegna A; Contarini M; Aliberti S; Casciaro R; Blasi F; Castellani C
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy.
    Zhou GC; Wang Z; Palipana AK; Andrinopoulou ER; Miranda Afonso P; McPhail GL; Siracusa CM; Gecili E; Szczesniak RD
    Respir Res; 2024 Apr; 25(1):187. PubMed ID: 38678203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one
    Daines CL; Tullis E; Costa S; Linnemann RW; Mall MA; McKone EF; Polineni D; Quon BS; Ringshausen FC; Rowe SM; Selvadurai H; Taylor-Cousar JL; Withers NJ; Ahluwalia N; Moskowitz SM; Prieto-Centurion V; Tan YV; Tian S; Weinstock T; Xuan F; Zhang Y; Ramsey B; Griese M;
    Eur Respir J; 2023 Dec; 62(6):. PubMed ID: 37945033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of ivacaftor in infants aged 1 to less than 4 months with cystic fibrosis.
    McNally P; Singh A; McColley SA; Davies JC; Higgins M; Liu M; Lu J; Rodriguez-Romero V; Shih JL; Rosenfeld M;
    J Cyst Fibros; 2024 May; 23(3):429-435. PubMed ID: 38580563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic Fibrosis: A Review.
    Ong T; Ramsey BW
    JAMA; 2023 Jun; 329(21):1859-1871. PubMed ID: 37278811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients.
    Gostelie R; Stegeman I; Berkers G; Bittermann J; Ligtenberg-van der Drift I; Kipshagen PV; de Winter-de Groot K; Speleman L
    PLoS One; 2020; 15(7):e0235638. PubMed ID: 32687499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CFTR modulator therapy on body composition as assessed by thoracic computed tomography: A follow-up study.
    Navas-Moreno V; Sebastian-Valles F; Rodríguez-Laval V; Knott-Torcal C; Marazuela M; de la Blanca NS; Arranz Martín JA; Girón RM; Sampedro-Núñez MA
    Nutrition; 2024 Jul; 123():112425. PubMed ID: 38621324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tezacaftor-ivacaftor use in routine care of adults with cystic fibrosis: a medicine use evaluation.
    Paterson I; Johnson C; MacGregor G
    Eur J Hosp Pharm; 2023 May; 30(3):142-146. PubMed ID: 34103394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis.
    Guimbellot JS; Ryan KJ; Anderson JD; Parker KL; Victoria Odom L; Rowe SM; Acosta EP
    Pediatr Pulmonol; 2022 Nov; 57(11):2745-2753. PubMed ID: 35927224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis.
    Taylor-Cousar JL; Robinson PD; Shteinberg M; Downey DG
    Lancet; 2023 Sep; 402(10408):1171-1184. PubMed ID: 37699418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tritherapy with cystic fibrosis transmembrane conductance regulator protein modulators in cystic fibrosis].
    Fielbaum Colodro O; Vidal Grell A; Méndez Yarur A; Sobarzo Clerc C
    Andes Pediatr; 2022 Dec; 93(6):898-905. PubMed ID: 37906807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.
    Martinez FJ; Criner GJ; Gessner C; Jandl M; Scherbovsky F; Shinkai M; Siler TM; Vogelmeier CF; Voves R; Wedzicha JA; Bartels C; Bottoli I; Byiers S; Cardenas P; Eckert JH; Gutzwiller FS; Knorr B; Kothari M; Parlikar R; Tanase AM; Franssen FME
    Am J Respir Crit Care Med; 2023 Aug; 208(4):417-427. PubMed ID: 37411039
    [No Abstract]   [Full Text] [Related]  

  • 20. Correlation between Ivacaftor-induced CFTR Activation in Airway Epithelial Cells and Improved Lung Function: A Proof-of-Concept Study.
    Debley JS; Barrow KA; Rich LM; Singh P; McKone EF; Nichols DP
    Ann Am Thorac Soc; 2020 Aug; 17(8):1024-1027. PubMed ID: 32421352
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.